Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer

Current Oncology Reports

Volumn 15, Issue 2, 2013, Pages 98-104

  Tang, Patricia A ^a   Heng, Daniel Y C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Programmed death 1; Prostate cancer; Renal cell carcinoma

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; AXITINIB; BMS 936559; EVEROLIMUS; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MDX 1105; MK 3475; MONOCLONAL ANTIBODY; NIVOLUMAB; PAZOPANIB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; COLITIS; COLON CANCER; DECREASED APPETITE; DIABETES MELLITUS; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSPNEA; ENDOPHTHALMITIS; FATIGUE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HUMAN; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNOREGULATION; INJECTION SITE REACTION; INTRACELLULAR SIGNALING; KIDNEY METASTASIS; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MYASTHENIA GRAVIS; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOIDOSIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THYROIDITIS; TREATMENT RESPONSE; TUMOR IMMUNITY; VITILIGO;

CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84879601217     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0284-2     Document Type: Article

References (46)

1. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81. doi: 10.1016/S0065-2776(06)90002-9.
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-9. doi: 10.1038/nature10673.
3. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992;258(5089):1795-8.
4. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828-36. doi: 10.1200/JCO.2011.38.0899.
5. • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64. doi: 10.1038/nrc3239. This is an excellent review explaining the basic science of immune checkpoints and the implications for cancer immunotherapy.
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. doi: 10.1056/NEJMoa1003466.
7. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26. doi: 10.1056/NEJMoa1104621.
8. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141-51.
9. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813-24. doi: 10.1093/intimm/dxm057.
10. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365-9. doi: 10.1038/70932.
11. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-34.
12. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-8. doi: 10.1038/85330.
13. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 2001;193(7):839-46.
14. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562-7. doi: 10.1038/nm863.
15. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293-7. doi: 10.1073/pnas.192461099.
16. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-77. doi: 10.1038/nri2326.
17. • Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of Anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65. doi: 10.1056/NEJMoa1200694. This article reviews the clinical activity and toxicity of anti-PD-L1 antibody BMS-936559 in patients with advanced solid tumors.
18. • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. doi: 10.1056/NEJMoa1200690. This article reviews the clinical activity and toxicity of anti-PD1 antibody BMS-936558 in patients with advanced solid tumors.
19. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;71(16):5393-9. doi: 10.1158/0008-5472.CAN-11-0993.
20. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-95.
21. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64(3):1140-5.
22. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. doi: 10.1038/nm730. Erratum, Nat Med 2002;8:1039.
23. Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010;116(8):1291-8. doi: 10.1182/blood-2010-01-265975.
24. Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011;187(3):1097-105. doi: 10.4049/jimmunol. 1003496.
25. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458(7235):206-10. doi: 10.1038/nature07662.
26. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13(23):6947-58. doi: 10.1158/1078-0432.CCR-07-0842.
27. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177(10):7398-405.
28. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14(11):3254-61. doi: 10.1158/1078-0432.CCR-07- 5164.
29. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22. doi: 10.1056/NEJMoa1001294.
30. Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, et al. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer. 2009;45(9):1664-72. doi: 10.1016/j.ejca.2009. 02.015.
31. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757-61. doi: 10.1158/1078-0432.CCR-06-2599.
32. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381-5. doi: 10.1158/0008-5472.CAN-05-4303.
33. Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17(7):1915-23. doi: 10.1158/1078-0432.CCR-10-0250.
34. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624.
35. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044-51. doi: 10.1158/1078-0432.CCR-07-4079.
36. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609.
37. Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Presented at the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2012. Abstract 2512.
38. Virtual meeting presentation accessed via http://www.asco.org/ASCOv2/ MultiMedia/Virtual+Meeting?&vmview=vm-session-presentations-view&confID= 114&sessionID=4763.
39. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9.
40. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9.
41. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol. 2005;23(28):6982-91. doi: 10.1200/JCO.2005.06.679.
42. Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009;15(5):1623-34. doi: 10.1158/1078-0432.CCR-08-1825.
43. Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer. 2012;130(8):1948-59. doi: 10.1002/ijc.26219.
44. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148-57. doi: 10.1158/1078-0432.CCR-08-1332.
45. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 2010;70(23):9599-610. doi: 10.1158/0008-5472.CAN-10-1293.
46. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514-22. doi: 10.1158/0008-5472.CAN-08-4709.